Promise and progress for functional and molecular imaging of response to targeted therapies

Pharmaceutical Research

Volumn 24, Issue 6, 2007, Pages 1172-1185

  Stephen, Renu M ^a   Gillies, Robert J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

DCE MRI; Diffusion Weighted MRI; FDG PET; HIF 1 ; Imaging biomarkers; PI3K AKT; Targeted therapies; VEGF

Indexed keywords

103D5R; 2 MORPHOLINO 8 PHENYLCHROMONE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTINEOPLASTIC AGENT; AP 23573; AP 23841; AXITINIB; BAY 579352; BEVACIZUMAB; CC 1779; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; HYPOXIA INDUCIBLE FACTOR 1; MONOCLONAL ANTIBODY DC101; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PX 478; PX 866; RAPAMYCIN; SEMAXANIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VATALANIB; WORTMANNIN;

CLINICAL TRIAL; COLORECTAL CANCER; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DISEASE MARKER; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; VON HIPPEL LINDAU DISEASE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BIOLOGICAL MARKERS; CLINICAL TRIALS; GLUCOSE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249006601     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9250-3     Document Type: Review

References (140)

1. W. R. Parulekar, and E. A. Eisenhauer. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J. Natl. Cancer Inst. 96:990-997 (2004).
2. R. G. Blasberg. Molecular imaging and cancer. Mol. Cancer Ther. 2:335-343 (2003).
3. J. L. Evelhoch, R. J. Gillies, G. S. Karczmar, J. A. Koutcher, R. J. Maxwell, O. Nalcioglu, N. Raghunand, S. M. Ronen, B. D. Ross, and H. M. Swartz. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2:152-165 (2000).
4. B. F. Jordan, K. Black, I. F. Robey, M. Runquist, G. Powis, and R. J. Gillies. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed. 18(7):430-439 (2005).
5. B. F. Jordan, M. Runquist, N. Raghunand, A. Baker, R. Williams, L. Kirkpatrick, G. Powis, and R. J. Gillies. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 7:475-485 (2005).
6. G. J. Kelloff, K. A. Krohn, S. M. Larson, R. Weissleder, D. A. Mankoff, J. M. Hoffman, J. M. Link, K. Z. Guyton, W. C. Eckelman, H. I. Scher, J. O'Shaughnessy, B. D. Cheson, C. C. Sigman, J. L. Tatum, G. Q. Mills, D. C. Sullivan, and J. Woodcock. The progress and promise of molecular imaging probes in oncologic drug development. Clin. Cancer Res. 11:7967-7985 (2005).
7. R. J. Gillies, Z. M. Bhujwalla, J. Evelhoch, M. Garwood, M. Neeman, S. P. Robinson, C. H. Sotak, and B. Van Der Sanden. Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2:139-151 (2000).
8. J. P. Galons, D. L. Morse, D. R. Jennings, and R. J. Gillies. Diffusion-weighted MRI and response to anti-cancer therapies. Isr. J. Chem. 43:91-101 (2003).
9. T. L. Chenevert, P. E. McKeever, and B. D. Ross. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin. Cancer Res. 3:1457-1466 (1997).
10. Y. Mardor, Y. Roth, Z. Lidar, T. Jonas, R. Pfeffer, S. E. Maier, M. Faibel, D. Nass, M. Hadani, A. Orenstein, J. S. Cohen, and Z. Ram. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 61:4971-4973 (2001).
11. Y. Mardor, R. Pfeffer, R. Spiegelmann, Y. Roth, S. E. Maier, O. Nissim, R. Berger, A. Glicksman, J. Baram, A. Orenstein, J. S. Cohen, and T. Tichler. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J. Clin. Oncol. 21:1094-1100 (2003).
12. D. E. Hall, B. A. Moffat, J. Stojanovska, T. D. Johnson, Z. Li, D. A. Hamstra, A. Rehemtulla, T. L. Chenevert, J. Carter, D. Pietronigro, and B. D. Ross. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin. Cancer Res. 10:7852-7859 (2004).
13. K. C. Lee, D. E. Hall, B. A. Hoff, B. A. Moffat, S. Sharma, T. L. Chenevert, C. R. Meyer, W. R. Leopold, T. D. Johnson, R. V. Mazurchuk, A. Rehemtulla, and B. D. Ross. Dynamic imaging of emerging resistance during cancer therapy. Cancer Res. 66:4687-4692 (2006).
14. B. A. Moffat, T. L. Chenevert, T. S. Lawrence, C. R. Meyer, T. D. Johnson, Q. Dong, C. Tsien, S. Mukherji, D. J. Quint, S. S. Gebarski, P. L. Robertson, L. R. Junck, A. Rehemtulla, and B. D. Ross. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc. Natl. Acad. Sci. U. S. A. 102:5524-5529 (2005).
15. P. A. Hein, C. Kremser, W. Judmaier, J. Griebel, K. P. Pfeiffer, A. Kreczy, E. B. Hug, P. Lukas, and A. F. DeVries. Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur. J. Radiol. 45:214-222 (2003).
16. M. Uhl, U. Saueressig, M. van Buiren, U. Kontny, C. Niemeyer, G. Kohler, K. Ilyasov, and M. Langer. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest. Radiol. 41:618-623 (2006).
17. R. J. Theilmann, R. Borders, T. P. Trouard, G. Xia, E. Outwater, J. Ranger-Moore, R. J. Gillies, and A. Stopeck. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6:831-837 (2004).
18. A. Dzik-Jurasz, C. Domenig, M. George, J. Wolber, A. Padhani, G. Brown, and S. Doran. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360:307-308 (2002).
19. L. Lemaire, F. A. Howe, L. M. Rodrigues, and J. R. Griffiths. Assessment of induced rat mammary tumour response to chemotherapy using the apparent diffusion coefficient of tissue water as determined by diffusion-weighted 1H-NMR spectroscopy in vivo. Magma 8:20-26 (1999).
20. M. Zhao, J. G. Pipe, J. Bonnett, and J. L. Evelhoch. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br. J. Cancer 73:61-64 (1996).
21. D. A. Beauregard, P. E. Thelwall, D. J. Chaplin, S. A. Hill, G. E. Adams, and K. M. Brindle. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br. J. Cancer 77:1761-1767 (1998).
22. J. P. Galons, M. I. Altbach, G. D. Paine-Murrieta, C. W. Taylor, and R. J. Gillies. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1:113-117 (1999).
23. D. Jennings, B. N. Hatton, J. Guo, J. P. Galons, T. P. Trouard, N. Raghunand, J. Marshall, and R. J. Gillies. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 4:255-262 (2002).
24. H. C. Thoeny, F. De Keyzer, F. Chen, V. Vandecaveye, E. K. Verbeken, B. Ahmed, X. Sun, Y. Ni, H. Bosmans, R. Hermans, A. van Oosterom, G. Marchal, and W. Landuyt. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 7:779-787 (2005).
25. A. M. Chinnaiyan, U. Prasad, S. Shankar, D. A. Hamstra, M. Shanaiah, T. L. Chenevert, B. D. Ross, and A. Rehemtulla. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 97:1754-1759 (2000).
26. E. Rustamzadeh, W. A. Hall, D. A. Todhunter, W. C. Low, H. Liu, A. Panoskaltsis-Mortari, and D. A. Vallera. Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice. Int. J. Cancer 118:2594-2601 (2006).
27. K. Turetschek, E. Floyd, D. M. Shames, T. P. Roberts, A. Preda, V. Novikov, C. Corot, W. O. Carter, and R. C. Brasch. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology. Magn. Reson. Med. 45:880-886 (2001).
28. B. A. Birnbaum, J. C. Weinreb, M. P. Fernandez, J. J. Brown, N. M. Rofsky, and S. W. Young. Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions. Initial findings. Clin. Imaging 18:21-27 (1994).
29. A. M. Lutz, J. K. Willmann, K. Goepfert, B. Marincek, and D. Weishaupt. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology 237:520-528 (2005).
30. P. L. Choyke, A. J. Dwyer, and M. V. Knopp. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 17:509-520 (2003).
31. M. V. Knopp, F. L. Giesel, H. Marcos, H. von Tengg-Kobligk, and P. Choyke. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn. Reson. Imaging 12:301-308 (2001).
32. W.R. Hendee and E.R. Ritenour. Medical Imaging Physics, Mobsy, St. Louis, 1992.
33. A. Quon, and S. S. Gambhir. FDG-PET and beyond: molecular breast cancer imaging. J. Clin. Oncol. 23:1664-1673 (2005).
34. R. Bos, J. J. van Der Hoeven, E. van Der Wall, P. van Der Groep, P. J. van Diest, E. F. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, and C. F. Molthoff. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J. Clin. Oncol. 20:379-387 (2002).
35. B. M. Burt, J. L. Humm, D. A. Kooby, O. D. Squire, S. Mastorides, S. M. Larson, and Y. Fong. Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia 3:189-195 (2001).
36. R. A. Gatenby, and R. J. Gillies. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4:891-899 (2004).
37. M. Kunkel, T. E. Reichert, P. Benz, H. A. Lehr, J. H. Jeong, S. Wieand, P. Bartenstein, W. Wagner, and T. L. Whiteside. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97:1015-1024 (2003).
38. E. Mochiki, H. Kuwano, H. Katoh, T. Asao, N. Oriuchi, and K. Endo. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J. Surg. 28:247-253 (2004).
39. A. Gennari, S. Donati, B. Salvadori, A. Giorgetti, P. A. Salvadori, O. Sorace, G. Puccini, P. Pisani, M. Poli, D. Dani, E. Landucci, G. Mariani, and P. F. Conte. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin. Breast Cancer 1:156-161 (2000); (discussion 162-163).
40. R. Kumar and A. Alavi. Fluorodeoxyglucose-PET in the management of breast cancer. Radiol. Clin. North Am. 42:1113-1122 (2004), ix.
41. J. S. Ryu, N. C. Choi, A. J. Fischman, T. J. Lynch, and D. J. Mathisen. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 35:179-187 (2002).
42. A. Dimitrakopoulou-Strauss, L. G. Strauss, and J. Rudi. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q. J. Nucl. Med. 47:8-13 (2003).
43. R. J. Gillies, P. A. Schornack, T. W. Secomb, and N. Raghunand. Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1:197-207 (1999).
44. H. E. Daldrup-Link, D. M. Shames, M. Wendland, A. Muhler, A. Gossmann, W. Rosenau, and R. C. Brasch. Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging. Acad. Radiol. 7:934-944 (2000).
45. M. Y. Su, Z. Wang, P. M. Carpenter, X. Lao, A. Muhler, and O. Nalcioglu. Characterization of N-ethyl-N-nitrosourea-induced malignant and benign breast tumors in rats by using three MR contrast agents. J. Magn. Reson. Imaging 9:177-186 (1999).
46. R. J. Maxwell, J. Wilson, V. E. Prise, B. Vojnovic, G. J. Rustin, M. A. Lodge, and G. M. Tozer. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed. 15:89-98 (2002).
47. C. Hayes, A. R. Padhani, and M. O. Leach. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 15:154-163 (2002).
48. M. Y. Su, Y. C. Cheung, J. P. Fruehauf, H. Yu, O. Nalcioglu, E. Mechetner, A. Kyshtoobayeva, S. C. Chen, S. Hsueh, C. E. McLaren, and Y. L. Wan. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J. Magn. Reson. Imaging 18:467-477 (2003).
49. K. Turetschek, A. Preda, V. Novikov, R. C. Brasch, H. J. Weinmann, P. Wunderbaldinger, and T. P. Roberts. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J. Magn. Reson. Imaging 20:138-144 (2004).
50. M. Port, C. Corot, I. Raynal, J. M. Idee, A. Dencausse, E. Lancelot, D. Meyer, B. Bonnemain, and J. Lautrou. Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. Invest. Radiol. 36:445-454 (2001).
51. A. Mavi, M. Urhan, J. Q. Yu, H. Zhuang, M. Houseni, T. F. Cermik, D. Thiruvenkatasamy, B. Czerniecki, M. Schnall, and A. Alavi. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J. Nucl. Med. 47:1440-1446 (2006).
52. J. Tseng, L. K. Dunnwald, E. K. Schubert, J. M. Link, S. Minoshima, M. Muzi, and D. A. Mankoff. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J. Nucl. Med. 45:1829-1837 (2004).
53. K. A. Phillips, S. Van Bebber, and A. M. Issa. Diagnostics and biomarker development: priming the pipeline. Nat. Rev. Drug Discov. 5:463-469 (2006).
54. J. A. DiMasi, R. W. Hansen, and H. G. Grabowski. The price of innovation: new estimates of drug development costs. J. Health Econ. 22:151-185 (2003).
55. E. Nadler, B. Eckert, and P. J. Neumann. Do oncologists believe new cancer drugs offer good value? Oncologist 11:90-95 (2006).
56. R. Weissleder. Molecular imaging in cancer. Science 312:1168-1171 (2006).
57. T. Sjoblom, S. Jones, L. D. Wood, D. W. Parsons, J. Lin, T. Barber, D. Mandelker, R. J. Leary, J. Ptak, N. Silliman, S. Szabo, P. Buckhaults, C. Farrell, P. Meeh, S. D. Markowitz, J. Willis, D. Dawson, J. K. Willson, A. F. Gazdar, J. Hartigan, L. Wu, C. Liu, G. Parmigiani, B. H. Park, K. E. Bachman, N. Papadopoulos, B. Vogelstein, K. W. Kinzler, and V. E. Velculescu. The consensus coding sequences of human breast and colorectal cancers. Science 7:7 (2006).
58. R. Simon, and A. Maitournam. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin. Cancer Res. 10:6759-6763 (2004).
59. R. J. Gillies and D. L. Morse. In vivo magnetic resonance spectroscopy in cancer. Annu. Rev. Biomed. Eng. 7:287-326 (2005).
60. J. A. DiMasi. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20:1-10 (2002).
61. J. Y. Blay, A. Le Cesne, L. Alberti, and I. Ray-Coquart. Targeted cancer therapies. Bul.l Cancer 92:E13-E18 (2005).
62. S. Faivre, S. Djelloul, and E. Raymond. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin. Oncol. 33:407-420 (2006).
63. S. R. Datta, A. Brunet, and M. E. Greenberg. Cellular survival: a play in three Akts. Genes Dev. 13:2905-2929 (1999).
64. I. Vivanco, and C. L. Sawyers. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2:489-501 (2002).
65. P. Blume-Jensenand, and T. Hunter. Oncogenic kinase signalling. Nature 411:355-365 (2001).
66. N. Gao, Z. Zhang, B. H. Jiang, and X. Shi. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun. 310:1124-1132 (2003).
67. M. Osaki, M. Oshimura, and H. Ito. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667-676 (2004).
68. A. Di Cristofano, P. Kotsi, Y. F. Peng, C. Cordon-Cardo, K. B. Elkon, and P. P. Pandolfi. Impaired Fas response and autoimmunity in Pten+/- mice. Science 285:2122-2125 (1999).
69. K. M. Nicholson, and N. G. Anderson. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 14:381-395 (2002).
70. B. T. Hennessy, D. L. Smith, P. T. Ram, Y. Lu, and G. B. Mills. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4:988-1004 (2005).
71. D. R. Alessi and P. Cohen. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 8:5562 (1998).
72. P. J. Coffer, J. Jin, and J. R. Woodgett. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 335:1-13 (1998).
73. N. T. Ihle, R. Williams, S. Chow, W. Chew, M. I. Berggren, G. Paine-Murrieta, D. J. Minion, R. J. Halter, P. Wipf, R. Abraham, L. Kirkpatrick, and G. Powis. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 3:763-772 (2004).
74. A. R. Gottschalk, A. Doan, J. L. Nakamura, D. Stokoe, and D. A. Haas-Kogan. Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int. J. Radiat. Oncol. Biol. Phys. 63:1221-1227 (2005).
75. L. Hu, C. Zaloudek, G. B. Mills, J. Gray, and R. B. Jaffe. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res. 6:880-886 (2000).
76. S. S. Ng, M. S. Tsao, T. Nicklee, and D. W. Hedley. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res. 7:3269-3275 (2001).
77. K. E. Rosenzweig, M. B. Youmell, S. T. Palayoor, and B. D. Price. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin. Cancer Res. 3:1149-1156 (1997).
78. M. B. Atkins, M. Hidalgo, W. M. Stadler, T. F. Logan, J. P. Dutcher, G. R. Hudes, Y. Park, S. H. Liou, B. Marshall, J. P. Boni, G. Dukart, and M. L. Sherman. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22:909-18 (2004).
79. E. Galanis, J. C. Buckner, M. J. Maurer, J. I. Kreisberg, K. Ballman, J. Boni, J. M. Peralba, R. B. Jenkins, S. R. Dakhil, R. F. Morton, K. A. Jaeckle, B. W. Scheithauer, J. Dancey, M. Hidalgo, and D. J. Walsh. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23:5294-5304 (2005).
80. L. A. DeGraffenried, L. Fulcher, W. E. Friedrichs, V. Grunwald, R. B. Ray, and M. Hidalgo. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann. Oncol. 15:1510-1516 (2004).
81. M. S. Neshat, I. K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J. J. Gibbons, H. Wu, and C. L. Sawyers. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U. S. A. 98:10314-10319 (2001).
82. K. Podsypanina, R. T. Lee, C. Politis, I. Hennessy, A. Crane, J. Puc, M. Neshat, H. Wang, L. Yang, J. Gibbons, P. Frost, V. Dreisbach, J. Blenis, Z. Gaciong, P. Fisher, C. Sawyers, L. Hedrick-Ellenson, and R. Parsons. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. U. S. A. 98:10320-10325 (2001).
83. Q. B. She, D. B. Solit, Q. Ye, K. E. O'Reilly, J. Lobo, and N. Rosen. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8:287-297 (2005).
84. G. L. Semenza. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol. Med. 7:345-350 (2001).
85. G. L. Semenza. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8:S62-S67 (2002).
86. G. L. Wang, B. H. Jiang, E. A. Rue, and G. L. Semenza. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U. S. A. 92:5510-5514 (1995).
87. A. C. Epstein, J. M. Gleadle, L. A. McNeill, K. S. Hewitson, J. O'Rourke, D. R. Mole, M. Mukherji, E. Metzen, M. I. Wilson, A. Dhanda, Y. M. Tian, N. Masson, D. L. Hamilton, P. Jaakkola, R. Barstead, J. Hodgkin, P. H. Maxwell, C. W. Pugh, C. J. Schofield, and P. J. Ratcliffe. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54 (2001).
88. M. Ivan, K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J. M. Asara, W. S. Lane, and W. G. Kaelin, Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464-468 (2001).
89. Y. S. Chun, M. S. Kim, and J. W. Park. Oxygen-dependent and -independent regulation of HIF-1alpha. J. Korean Med. Sci. 17:581-588 (2002).
90. L. E. Huang, J. Gu, M. Schau, and H. F. Bunn. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 95:7987-7992 (1998).
91. P. H. Maxwell, M. S. Wiesener, G. W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275 (1999).
92. A. Zagorska, and J. Dulak. HIF-1: the knowns and unknowns of hypoxia sensing. Acta Biochim. Pol. 51:563-585 (2004).
93. K. L. Talks, H. Turley, K. C. Gatter, P. H. Maxwell, C. W. Pugh, P. J. Ratcliffe, and A. L. Harris. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157:411-421 (2000).
94. H. Zhong, A. M. De Marzo, E. Laughner, M. Lim, D. A. Hilton, D. Zagzag, P. Buechler, W. B. Isaacs, G. L. Semenza, and J. W. Simons. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830-5835 (1999).
95. I. F. Robey, A. D. Lien, S. J. Welsh, B. K. Baggett, and R. J. Gillies. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 7:324-330 (2005).
96. K. Kasuno, S. Takabuchi, K. Fukuda, S. Kizaka-Kondoh, J. Yodoi, T. Adachi, G. L. Semenza, and K. Hirota. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J. Biol. Chem. 279:2550-2558 (2004). Epub 2003 Nov 4.
97. R. Fukuda, K. Hirota, F. Fan, Y. D. Jung, L. M. Ellis, and G. L. Semenza. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277:38205-38211 (2002).
98. C. Treins, S. Giorgetti-Peraldi, J. Murdaca, G. L. Semenza, and E. Van Obberghen. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277:27975-27981 (2002).
99. E. Laughner, P. Taghavi, K. Chiles, P. C. Mahon, and G. L. Semenza. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol. 21:3995-4004 (2001).
100. R. Fukuda, B. Kelly, and G. L. Semenza. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 63:2330-2334 (2003).
101. R. Bos, H. Zhong, C. F. Hanrahan, E. C. Mommers, G. L. Semenza, H. M. Pinedo, M. D. Abeloff, J. W. Simons, P. J. van Diest, and E. van der Wall. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst. 93:309-314 (2001).
102. D. Zagzag, H. Zhong, J. M. Scalzitti, E. Laughner, J. W. Simons, and G. L. Semenza. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606-2618 (2000).
103. G. L. Semenza. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3:721-732 (2003).
104. K. Lee, R. A. Roth, and J. J. Lapres. Hypoxia, drug therapy and toxicity. Pharmacol. Ther. 11:11 (2006).
105. S. Welsh, R. Williams, L. Kirkpatrick, G. Paine-Murrieta, and G. Powis. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 3:233-244 (2004).
106. C. Tan, R. G. de Noronha, A. J. Roecker, B. Pyrzynska, F. Khwaja, Z. Zhang, H. Zhang, Q. Teng, A. C. Nicholson, P. Giannakakou, W. Zhou, J. J. Olson, M. M. Pereira, K. C. Nicolaou, and E. G. Van Meir. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 65:605-612 (2005).
107. C. A. Cuenod, L. Fournier, D. Balvay, and J. M. Guinebretiere. Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdom. Imaging 31:188-193 (2006).
108. D. Hanahan, and J. Folkman. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364 (1996).
109. R. P. Hill, K. De Jaeger, A. Jang, and R. Cairns. pH, hypoxia and metastasis. Novartis Found. Symp. 240:154-165 (2001); (discussion 165-168).
110. P. Carmeliet and R. K. Jain. Angiogenesis in cancer and other diseases. Nature 407:249-257 (2000).
111. P. Carmeliet, V. Ferreira, G. Breier, S. Pollefeyt, L. Kieckens, M. Gertsenstein, M. Fahrig, A. Vandenhoeck, K. Harpal, C. Eberhardt, C. Declercq, J. Pawling, L. Moons, D. Collen, W. Risau, and A. Nagy. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439 (1996).
112. N. Ferrara, K. Carver-Moore, H. Chen, M. Dowd, L. Lu, K. S. O'Shea, L. Powell-Braxton, K. J. Hillan, and M. W. Moore. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442 (1996).
113. W. Risau and V. Lemmon. Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev. Biol. 125:441-450 (1988).
114. V. Goede, T. Schmidt, S. Kimmina, D. Kozian, and H. G. Augustin. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab. Invest. 78:1385-1394 (1998).
115. Z. Zhou, J. Wang, R. Cao, H. Morita, R. Soininen, K. M. Chan, B. Liu, Y. Cao, and K. Tryggvason. Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res. 64:4699-4702 (2004).
116. K. A. Thomas. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 271:603-606 (1996).
117. T. L. Haas, and J. A. Madri. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc. Med. 9:70-77 (1999).
118. J. E. Nor, J. Christensen, D. J. Mooney, and P. J. Polverini. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154:375-384 (1999).
119. J. Tran, J. Rak, C. Sheehan, S. D. Saibil, E. LaCasse, R. G. Korneluk, and R. S. Kerbel. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun. 264:781-788 (1999).
120. A. R. Pries, B. Reglin, and T. W. Secomb. Structural response of microcirculatory networks to changes in demand: information transfer by shear stress. Am. J. Physiol. Heart Circ. Physiol. 284:H2204-H2212 (2003).
121. S. Rockwell, J. Yuan, S. Peretz, and P. M. Glazer. Genomic instability in cancer. Novartis Found. Symp. 240:133-142; (2001) (discussion 142-151).
122. R. J. Gillies, N. Raghunand, G. S. Karczmar, and Z. M. Bhujwalla. MRI of the tumor microenvironment. J. Magn. Reson. Imaging 16:430-450 (2002).
123. N. Raghunand, R. A. Gatenby, and R. J. Gillies. Microenvironmental and cellular consequences of altered blood flow in tumours. Br. J. Radiol. 76:S11-S22 (2003).
124. J. C. Lee, N. H. Chow, S. T. Wang, and S. M. Huang. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer 36:748-753 (2000).
125. Y. Liang, R. A. Brekken, and S. M. Hyder. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr. Relat. Cancer 13:905-919 (2006).
126. H. Takizawa, K. Kondo, H. Fujino, K. Kenzaki, T. Miyoshi, S. Sakiyama, and A. Tangoku. The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer. Br. J. Cancer 95:75-79 (2006).
127. G. Soufla, S. Sifakis, S. Baritaki, A. Zafiropoulos, E. Koumantakis, and D. A. Spandidos. VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett. 221:105-118 (2005).
128. N. Ferrara. VEGF as a therapeutic target in cancer. Oncology 69:11-16 (2005).
129. FDA. New targeted therapy for rare stomach, kidney cancers. FDA Consum. 40:5 (2006).
130. S. B. Wedam, J. A. Low, S. X. Yang, C. K. Chow, P. Choyke, D. Danforth, S. M. Hewitt, A. Berman, S. M. Steinberg, D. J. Liewehr, J. Plehn, A. Doshi, D. Thomasson, N. McCarthy, H. Koeppen, M. Sherman, J. Zujewski, K. Camphausen, H. Chen, and S. M. Swain. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24:769-777 (2006).
131. B. Morgan, A. L. Thomas, J. Drevs, J. Hennig, M. Buchert, A. Jivan, M. A. Horsfield, K. Mross, H. A. Ball, L. Lee, W. Mietlowski, S. Fuxuis, C. Unger, K. O'Byrne, A. Henry, G. R. Cherryman, D. Laurent, M. Dugan, D. Marme, and W. P. Steward. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 21:3955-3964 (2003).
132. M. Rudin, P. M. McSheehy, P. R. Allegrini, M. Rausch, D. Baumann, M. Becquet, K. Brecht, J. Brueggen, S. Ferretti, F. Schaeffer, C. Schnell, and J. Wood. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo. NMR Biomed. 18:308-321 (2005).
133. G. Liu, H. S. Rugo, G. Wilding, T. M. McShane, J. L. Evelhoch, C. Ng, E. Jackson, F. Kelcz, B. M. Yeh, F. T. Lee, Jr., C. Charnsangavej, J. W. Park, E. A. Ashton, H. M. Steinfeldt, Y. K. Pithavala, S. D. Reich, and R. S. Herbst. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J. Clin. Oncol. 23:5464-5473 (2005).
134. K. L. Li, L. J. Wilmes, R. G. Henry, M. G. Pallavicini, J. W. Park, D. D. Hu-Lowe, T. M. McShane, D. R. Shalinsky, Y. J. Fu, R. C. Brasch, and N. M. Hylton. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J. Magn. Reson. Imaging 22:511-519 (2005).
135. P. Marzola, A. Degrassi, L. Calderan, P. Farace, E. Nicolato, C. Crescimanno, M. Sandri, A. Giusti, E. Pesenti, A. Terron, A. Sbarbati, and F. Osculati. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin. Cancer Res. 11:5827-5832 (2005).
136. B. Giantonio, D. Levy, P. O'Dwyer, N. Meropol, P. Catalano, and A. Benson, 3rd. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann. Oncol. 17:1399-1403 (2006).
137. H. I. Hurwitz, L. Fehrenbacher, J. D. Hainsworth, W. Heim, J. Berlin, E. Holmgren, J. Hambleton, W. F. Novotny, and F. Kabbinavar. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 23:3502-3508 (2005).
138. A. Preda, V. Novikov, M. Moglich, K. Turetschek, D. M. Shames, R. C. Brasch, F. M. Cavagna, and T. P. Roberts. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J. Magn. Reson. Imaging 20:865-873 (2004).
139. W. B. Pope, A. Lai, P. Nghiemphu, P. Mischel, and T. F. Cloughesy. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258-1260 (2006).
140. R. R. Jennens, M. A. Rosenthal, G. J. Lindeman, and M. Michael. Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. Urol. Oncol. 22:193-196 (2004).